Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Verapamil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 3/20 | 0.96 |
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 0.96 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 0.96 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 0.96 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.96 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.96 |
| ▸ | TSHR | P16473 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | MEN1 | O00255 | 3/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.96 |
| ▸ | HTR1A | P08908 | 2/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.96 |
| ▸ | DRD2 | P14416 | 2/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.96 |
| ▸ | HTR2A | P28223 | 2/20 | 0.96 |
| ▸ | HTR2C | P28335 | 2/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexverapamil SCHEMBL15531745 | 1.00 | ABCB1 (0.96) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Dexverapamil SCHEMBL30402443 | 0.98 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29440902 | 0.98 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29450364 | 0.98 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29450374 | 0.98 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Dexverapamil SCHEMBL33297 | 0.98 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL29064783 | 0.98 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL1902363 | 0.98 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| (S)-Verapamil SCHEMBL29768846 | 0.98 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR | |
| Verapamil SCHEMBL16742 | 0.98 | ABCB1 (1.00) | ABCB1CYP3A4ABCC1KCNH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5948 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680201-A1 | COMPOSITIONS AND USES THEREOF FOR STABILIZATION OF BLOOD SAMPLE COMPONENTS | Streck LLC (US) | 2026-01-21 | — | — | EP | claimed |
| US-12478586-B2 | Small molecular drug-loaded polymer vesicle, preparation method therefor and use thereof | SOOCHOW UNIVERSITY (CN) | 2025-11-25 | — | — | US | claimed |
| US-12433899-B2 | Therapeutics and method for treating osteoarthritis | CALOSYN PHARMA INC. (US) | 2025-10-07 | — | — | US | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| CN-115536547-B | Preparation method of verapamil hydrochloride | 北京新领先医药科技发展有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-120076796-A | Oral pharmaceutical dosage form for gastric retention | 南京三迭纪医药科技有限公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2025097521-A1 | DRUG FOR TREATING OR ALLEVIATING HEART FAILURE | 上海水大技术转移有限公司 | 2025-05-15 | — | — | WO | claimed |
| CN-119909040-A | Verapamil hydrochloride sustained-release capsule and preparation method thereof | 南通联亚药业股份有限公司 | 2025-05-02 | — | — | CN | claimed |
| US-20250120937-A1 | THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITIS | CALOSYN PHARMA INC. | 2025-04-17 | — | — | US | claimed |
| WO-2025038939-A9 | POROUS PELLETS AND PROCESS OF MANUFACTURING THE SAME | SPI PHARMA, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| US-5169638-A | Powder filled capsules | E. R. SQUIBB & SONS, INC. (US) | 1992-12-08 | — | — | US | claimed |
| EP-0508653-A1 | Sustained-release pharmaceutical preparation and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1992-10-14 | — | — | EP | claimed |
| EP-0420042-B1 | SOLID PHARMACEUTICAL FORM WITH A HIGH VERAPAMIL CONTENT | KNOLL AG (DE) | 1992-07-15 | — | — | EP | claimed |
| EP-0217778-B1 | GALENICAL FORMS FOR THE SUSTAINED RELEASE OF VERAPAMIL, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | "PHARLYSE", Société Anonyme (LU) | 1992-05-20 | — | — | EP | claimed |
| EP-0463877-A1 | Controlled release pharmaceutical preparation | TANABE SEIYAKU CO., LTD. (JP) | 1992-01-02 | — | — | EP | claimed |
| EP-0446753-A1 | Therapeutic compositions with controlled release of medicaments supported on crosslinked polymers and coated with polymer films and their preparation process | VECTORPHARMA INTERNATIONAL S.P.A. (IT) | 1991-09-18 | — | — | EP | claimed |
| US-4863742-A | PELLETS, VERAPAMIL | ELAN CORPORATION PLC (IE) | 1989-09-05 | — | — | US | claimed |
| US-4832958-A | HYPOTENSIVE AGENTS | PHARLYSE SOCIETE ANONYME (LU) | 1989-05-23 | — | — | US | claimed |
| US-4792452-A | PH DEPENDENT POLYMER, PH INDEPENDENT HYDROCARBON GELLING AGENT AND BINDER | E. R. SQUIBB & SONS, INC. (US) | 1988-12-20 | — | — | US | claimed |
| US-4753802-A | SUSTAINED RELEASE, CELLULOSE ACETATE COMPARTMENTS | ALZA CORPORATION (US) | 1988-06-28 | — | — | US | claimed |